LENZ Therapeutics Achieves Success in Phase 3 Trial for LNZ100 Treatment of Presbyopia
Wednesday, 3 April 2024, 11:58
LENZ Therapeutics Excels in Phase 3 Trial for LNZ100
LENZ Therapeutics (LENZ) stock rises after positive results from Phase 3 trials for its lead asset, LNZ100, in treating presbyopia.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.